SCHEMBL20184050

SCHEMBL20184050

CC(C)(C)OC(=O)N1Cc2ccc(C#N)cc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.44
MTOR P42345 2/20 0.44
AR P10275 1/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
GPR119 Q8TDV5 4/20 0.41
DRD2 P14416 1/20 0.40
NR1H2 P55055 2/20 0.38
ESR2 Q92731 1/20 0.38
ALK Q9UM73 1/20 0.38
CASP3 P42574 1/20 0.38
BTK Q06187 1/20 0.37
RIPK1 Q13546 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
NAMPT P43490 1/20 0.36
EGLN2 Q96KS0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22374272 0.90 PIK3CA (0.44) PIK3CAMTORARHTR2AHTR2C
SCHEMBL21461289 0.82 ESR2 (0.53) PIK3CAMTORGPR119DRD2NR1H2
SCHEMBL29338553 0.82 PIK3CA (0.47) PIK3CAMTORHTR2AHTR2CGPR119
SCHEMBL2145067 0.81 NR1H2 (0.54) PIK3CAMTORGPR119DRD2NR1H2
SCHEMBL17141692 0.81 PIK3CA (0.46) PIK3CAMTORNR1H2ESR2DDB1
SCHEMBL18863339 0.81 PIK3CA (0.46) PIK3CAMTORGPR119NR1H2ESR2
SCHEMBL30884565 0.80 PIK3CA (0.46) PIK3CAMTORHTR2AHTR2CESR2
SCHEMBL30681394 0.79 PIK3CA (0.45) PIK3CAMTORHTR2AHTR2CGPR119
SCHEMBL23060613 0.78 PDE4B (0.41) ARGPR119ALKNAMPTEGLN2
SCHEMBL29814717 0.77 KDM4E (0.51) PIK3CAMTORNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111848598-B Heterocyclic compound, application thereof and composition containing same 健艾仕生物医药有限公司 2024-12-10 CN disclosed
US-20230099441-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME GENEROS BIOPHARMA LTD. (CN) 2023-03-30 US disclosed
WO-2020216378-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2020-10-29 WO disclosed
WO-2020216378-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2020-10-29 WO disclosed
US-10357484-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-07-23 US disclosed
US-20190008836-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-10 US disclosed
EP-3327019-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230099441-A1 HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME STAT5A, STAT5B, JAK2 PIK3CA 407/4885MTOR 61/4885AR 629/4885
US-10357484-B2 Heterocyclic compound HDAC1, HDAC11, HDAC5 PIK3CA 3764/4885MTOR 822/4885AR 2436/4885
US-20190008836-A1 HETEROCYCLIC COMPOUND HDAC1, HDAC11, HDAC5 PIK3CA 3764/4885MTOR 822/4885AR 2436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.